This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 92 trials Clear all
Filter by:

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, N...
    Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, N...
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-486 (5-azacitidine), Drug: Duvelisib, Drug: Romidepsin, Drug: Doxorubicin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-486 (5-azacitidine), Drug: Duvelisib, Drug: Romidepsin, Drug: Doxorubicin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Brief Summary

Background: T-cell lymphomas (TCLs) are rare cancers. Many types of TCLs do not develop in the lymph nodes but in places like the skin, spleen, and bone marrow. Researchers want to see if a mix of 4 drugs can help people with TCL. Objective: To test if the combination of romidepsin, CC-486 (5-azacitidine), duvelisib, and doxorubicin can be used safely in people with TCL. Eligibility: Adults 18 and older with TCL that is newly diagnosed or that returned after or did not respond to standard treatments. Design: Participants will be screened on a separate protocol. They may have a tumor biopsy. Participants will have medical histories, medicine reviews, and physical exams. Their ability to do daily activities will be assessed. They will have blood and urine tests. Participants will take duvelisib and CC-486 (5-azacitidine) by mouth. They will get romidepsin and doxorubicin by intravenous infusion. They will take the drugs for up to eight 21-day cycles. They will keep a medicine diary. Participants will have a bone marrow aspiration and/or biopsy. Bone marrow will be taken through a needle inserted in the hip. Participants will have tumor imaging scans. Some may have a brain MRI and lumbar puncture. Some may have skin assessments. Participants will give blood, saliva, and tumor samples for research. Participants will have a safety visit 30 days after treatment ends. Then they will have follow-up visits every 60 days for 6 months, then every 90 days for 2 years, and then every 6 months for 2 years. Then they will have yearly visits until their disease gets worse or they start a new treatment....

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Breast Carcin...
    Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Breast Carcin...
  • Phase Phase 1
    Phase 1
INTERVENTION

Other: Pharmacological Study, Drug: Romidepsin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Other: Pharmacological Study, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma, Non-Hodgkin's Lymphoma
    Multiple Myeloma, Non-Hodgkin's Lymphoma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: Romidepsin, Drug: Lenalidomide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Romidepsin, Drug: Lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut, United States

Brief Summary

The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Relapsed/Refractory T-cell Lymphomas
    Lymphoma, Relapsed/Refractory T-cell Lymphomas
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Romidepsin, Drug: Bortezomib, Drug: duvelisib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Romidepsin, Drug: Bortezomib, Drug: duvelisib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Stanford University Medical Center, Stanford, California, United States

Brief Summary

The purpose of this study is to test the safety of a study drug called duvelisib.

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Colorectal Cancer
    Colorectal Cancer
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Oral CC - 486, Drug: Romidepsin, Drug: MK - 3475

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Oral CC - 486, Drug: Romidepsin, Drug: MK - 3475

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition T Cell Lymphoma
    T Cell Lymphoma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: Tenalisib, Drug: Romidepsin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Tenalisib, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Brief Summary

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition T Cell Non-Hodgkin Lymphoma
    T Cell Non-Hodgkin Lymphoma
  • Phase Phase 2
    Phase 2
INTERVENTION

Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Eligibility
  • Ages: 16 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moffitt Cancer Center, Tampa, Florida, United States

Brief Summary

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic ...
    Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic ...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: Ro-CHOEP-21 (PHASE I), Drug: Ro-CHOEP-21 (PHASE II)

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Ro-CHOEP-21 (PHASE I), Drug: Ro-CHOEP-21 (PHASE II)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Brief Summary

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Hiv
    Hiv
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Romidepsin, Drug: 3BNC117, Drug: Antiretrovirals

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Romidepsin, Drug: 3BNC117, Drug: Antiretrovirals

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Infectious Diseases, Aalborg, Denmark

Brief Summary

To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

  • Status Recruiting
    Recruiting
  • Condition Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Ade...
    Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Ade...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: Romidepsin, Drug: Azacitidine, Drug: nab-Paclitaxel, Drug: Gemcitabine, Drug: Durvalumab, Drug: Lenalidomide capsule

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Romidepsin, Drug: Azacitidine, Drug: nab-Paclitaxel, Drug: Gemcitabine, Drug: Durvalumab, Drug: Lenalidomide capsule

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Universitätsklinikum Essen, Essen, Germany

Brief Summary

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients with controlled disease after 3 cycles (Part 1).